Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Fresh data revealed smartphone and tablet users are increasingly targeted by online crooks.
Children whose parents have divorced are driven to drink or drugs, new research suggests.
Paul Gascoigne has spoken about his ongoing battle with alcoholism, admitting that "the only person who can save me is me".